{"analyses":[{"ciLowerLimit":"1.61","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.63","estimateComment":"Odds Ratios in this Statistical Analysis corresponds to all four time points.","groupDescription":"Physical Functioning: Parents of 160 SR-ALL patients enrolled on Children's Oncology Group (COG) therapeutic trial AALL0331 at 31 sites completed the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales (physical, emotional and social functioning) and Family Assessment Device-General Functioning (FAD-GF) at 1, 6 and 12 months after diagnosis, and 3 months post-therapy.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Odds Ratio (OR)","paramValue":"5.17","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"1.21","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.27","estimateComment":"Odds Ratios in this Statistical Analysis corresponds to all four time points","groupDescription":"Social Functioning: Parents of 160 SR-ALL patients enrolled on Children's Oncology Group (COG) therapeutic trial AALL0331 at 31 sites completed the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales (physical, emotional and social functioning) and Family Assessment Device-General Functioning (FAD-GF) at 1, 6 and 12 months after diagnosis, and 3 months post-therapy.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Odds Ratio (OR)","paramValue":"1.99","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"1.03","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.34","estimateComment":"Odds Ratios in this Statistical Analysis corresponds to all four time points","groupDescription":"Parents of 160 SR-ALL patients enrolled on Children's Oncology Group (COG) therapeutic trial AALL0331 at 31 sites completed the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales (physical, emotional and social functioning) and Family Assessment Device-General Functioning (FAD-GF) at 1, 6 and 12 months after diagnosis, and 3 months post-therapy.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Odds Ratio (OR)","paramValue":"1.85","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.6","upperLimit":"83.1","value":"76.39"}]}],"title":"Physical Impairment 1 mth after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.2","upperLimit":"51.7","value":"42.75"}]}],"title":"Physical Impairment 6 mths after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.9","upperLimit":"37.8","value":"29.41"}]}],"title":"Physical Impairment 12 mths after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.2","upperLimit":"37.9","value":"27.84"}]}],"title":"Physical Impairment 3 mths post therapy"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"51.9","value":"43.36"}]}],"title":"Social Impairment 1 mth after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.7","upperLimit":"31.9","value":"23.66"}]}],"title":"Social Impairment 6 mths after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.7","upperLimit":"31.6","value":"23.53"}]}],"title":"Social Impairment 12 mths after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.4","upperLimit":"35.7","value":"25.77"}]}],"title":"Social Impairment 3 mths post-therapy"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.9","upperLimit":"47.4","value":"38.89"}]}],"title":"Emotional Impairment 1 mth after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.5","upperLimit":"25.2","value":"17.56"}]}],"title":"Emotional Impairment 6 mths after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.6","upperLimit":"21.0","value":"13.97"}]}],"title":"Emotional Impairment 12 mths after diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.6","upperLimit":"15.6","value":"8.25"}]}],"title":"Emotional Impairment 3 mths post-therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"}],"units":"Participants"}],"description":"To identify potentially modifiable factors associated with impaired health related quality of life (HRQOL) at different periods of therapy in the patients who are SR-average enrolled on the standard risk ALL study.Standardized scores will be computed for child function using the gender and age-adjusted scores available from normative data from a healthy population of about 10,000 children. The various domains of family functioning will be assessed using well-validated instruments and analyzed as a dichotomous variable (impaired vs. non-impaired family functioning). Multiple regression analysis will be used to test the effect of family functioning (adjusted for therapy given, age at diagnosis, gender, socioeconomic status and other factors) on child function.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients for induction therapy.","id":"OG000","title":"Induction Therapy"}],"paramType":"NUMBER","populationDescription":"This analysis is restricted to the 160 SR-ALL patients enrolled on Children's Oncology Group (COG) therapeutic trial AALL0331 at 31 sites, who consented to and completed the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales (physical, emotional and social functioning).","reportingStatus":"POSTED","timeFrame":"At 1, 6 and 12 months after diagnosis and, 3 months post-therapy","title":"Health-related Quality of Life Relative to Physical, Social and Emotional Impairment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}